Continuing Medical Education

These continuing medical education opportunities feature leading experts in lung health and respiratory care, providing state of the art education and trends in diagnosis and treatment of patients with lung disease. The opportunities below range from general pulmonary to concentration on specialized subjects such as asthma and COPD, and all provide Continuing Education Credits (CME) in adherence to the guidelines set forth by the Accreditation Council for Continuing Medical Education (ACCME).

Cost-Free Continuing Medical Education Opportunities

• Asthma Educator Institute
  

  This is a professional development course providing education on asthma guidelines-based care for patients and their families and provides the knowledge you need to sit for the National Asthma Educator Certification Board exam. This course includes continuing education credits and is offered virtually.

• COPD Educator Course
  This course builds knowledge and skills of health care professionals to treat and manage COPD. This course includes continuing education credits and is offered virtually.

• Implementation and Interpretation of Spirometry
  The Implementation and Interpretation of Spirometry in the Primary Care Practice training course is designed especially for healthcare professionals who have the responsibility to administer the spirometry test and primary care providers who interpret the results to diagnose and treat lung disease.

• Washington Thoracic Society Chest Disease Conference and Winter Lung Day
  The Washington Thoracic Society Chest Disease Conference and Winter Lung Day is designed to cover a broad spectrum of clinical pulmonary and critical care topics geared toward physicians and allied health professionals in pulmonary, critical care, and sleep medicine, thoracic surgery, allergy, infectious disease, family practice and internal medicine. Both live and virtual participation is offered.

• Broadening Treatments for Patients with Newly Diagnosed NSCLC
  This on-demand activity will review practice-changing data on the efficacy and safety of new and emerging treatment strategies with checkpoint inhibitors. The panel of medical experts discuss recent therapy approvals, selection of patients based on PD-L and mutational status, minimizing immune-related adverse events and improving patient quality of life. Get the latest medical science and earn AMA PRA Category 1 Credit. Provided in collaboration with PlatformQ Health Education, LLC.

• Emerging Evidence on Antibody-Drug Conjugates in Advanced NSCLC: Focus on TROP2
  The development of antibody-drugs conjugates (ADCs) that target tumor-associated calcium signal transducer 2 (TROP2) has the potential to change the treatment paradigm for patients with advanced non-small cell lung cancer (NSCLC), including those with or without actionable genomic alterations. This educational activity will provide a better understanding of the role of TROP2 in NSCLC, the mechanism of action of TROP2-targeted ADCs, and how the latest data—and ongoing phase 3 trials—will help inform the potential use of these agents in patient care. This activity has been designed to address the educational needs of oncology clinicians including physicians, nurse practitioners, and PAs who manage patients with lung cancer. It may also be of benefit to other healthcare professionals who have an interest in the topic.